Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients
{{output}}
Background: Radium-223-dichloride (Ra-223) is an alpha-emitting, bone seeking radionuclide therapy approved for patients with metastatic castration-resistant prostate cancer (mCRPC). In the fall of 2014, a global temporary shorta... ...
